{
    "clinical_study": {
        "@rank": "74033", 
        "arm_group": [
            {
                "arm_group_label": "TD-6450", 
                "arm_group_type": "Experimental", 
                "description": "TD-6450 capsules"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo capsules"
            }
        ], 
        "brief_summary": {
            "textblock": "This proof of concept study is designed to evaluate the safety, tolerability,\n      pharmacokinetics, and antiviral activity of TD-6450 in treatment na\u00efve subjects with GT-1,\n      GT-2 or GT-3 chronic HCV."
        }, 
        "brief_title": "TD-6450 MAD Study in HCV Infected Subjects", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hepatitis C", 
            "HCV"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is HCV antibody positive\n\n          -  Subject is treatment na\u00efve, with no history of exposure (single or multiple dose) to\n             interferon, ribavirin or direct acting antivirals.\n\n          -  Subject has had a liver biopsy within 3 years or Fibroscan evaluation within 6 months\n             prior to Screening that clearly excludes cirrhosis.   If not available prior to\n             Screening, the absence of cirrhosis must be confirmed prior to subject enrollment\n             using either Fibroscan or Fibrosure\u00ae.\n\n          -  Subject is negative for hepatitis A (HAV), hepatitis B (HBV), and human\n             immunodeficiency virus (HIV).\n\n        Exclusion Criteria:\n\n          -  Subject has prior histological evidence of cirrhosis or current clinical evidence of\n             cirrhosis in the opinion of the investigator.\n\n          -  Subject has a history or evidence of non-hepatitis C chronic liver disease.\n\n          -  Subject has an estimated creatinine clearance of <80 ml/min if 18-60 years of age,\n             inclusive; or <70 ml/min if >60 years of age, calculated using the Cockcroft-Gault\n             equation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02116543", 
            "org_study_id": "0110"
        }, 
        "intervention": [
            {
                "arm_group_label": "TD-6450", 
                "intervention_name": "TD-6450", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Hepatitis C", 
            "HCV"
        ], 
        "lastchanged_date": "May 22, 2014", 
        "location": {
            "contact": {
                "last_name": "Eric Lawitz, M.D.", 
                "phone": "210-572-4997"
            }, 
            "facility": {
                "address": {
                    "city": "San Antonio", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "78215"
                }, 
                "name": "Texas Liver Institute"
            }, 
            "investigator": {
                "last_name": "Eric Lawitz, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double-Blinded, Randomized, Placebo-Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Antiviral Activity of TD-6450, a NS5A Inhibitor, in Treatment Na\u00efve Subjects With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)", 
        "overall_contact": {
            "email": "Rkohler@theravance.com", 
            "last_name": "Roger Kohler", 
            "phone": "650-808-6400"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number, type, severity, and association of treatment emergent adverse events.", 
            "measure": "Adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "28 Days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02116543"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Cmax", 
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }, 
            {
                "description": "Tmax", 
                "measure": "Tmax", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }, 
            {
                "measure": "AUC0-t", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }, 
            {
                "description": "AUC0-\u221e", 
                "measure": "AUC0-\u221e", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }, 
            {
                "measure": "AUC0-24", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }, 
            {
                "description": "Change from baseline in HCV RNA", 
                "measure": "Antiviral Activity", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }, 
            {
                "description": "t1/2", 
                "measure": "t1/2", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }
        ], 
        "source": "Theravance, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Theravance, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}